Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PRKACA | P17612 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | PRKX | P51817 | 1/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135695 | 0.91 | HPGD (0.61) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL7853972 | 0.89 | MMP13 (0.58) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL6358788 | 0.86 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2HPGDRAB9AMAPT | |
| SCHEMBL17695173 | 0.84 | MMP13 (0.70) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL15649601 | 0.84 | MMP13 (0.62) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL13744517 | 0.84 | ALDH1A1 (0.62) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL28880825 | 0.83 | SMN1; SMN2 (0.57) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL23978716 | 0.83 | MMP13 (0.68) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL30279331 | 0.83 | MMP13 (0.68) | MMP13ALDH1A1HTTSMN1; SMN2HPGD | |
| SCHEMBL3872357 | 0.83 | MMP13 (0.68) | MMP13ALDH1A1HTTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105456-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-16 | — | — | US | claimed |
| US-6969582-B2 | Silver halide emulsion containing iridium dopant | EASTMAN KODAK COMPANY (US) | 2005-11-29 | — | — | US | claimed |
| US-20050233266-A1 | SILVER HALIDE EMULSION CONTAINING IRIDIUM DOPANT | QUALEX INC. | 2005-10-20 | — | — | US | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| EP-2970124-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190083457-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS FOR PROTECTING, EXPANDING AND INCREASING THE POTENCY OF HEMATOPOIETIC STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-03-21 | — | — | US | disclosed |
| WO-2019055169-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS FOR PROTECTING, EXPANDING AND INCREASING THE POTENCY OF HEMATOPOIETIC STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-20110105602-A2 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-05-05 | — | — | US | disclosed |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-26 | — | — | US | disclosed |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-26 | — | — | US | disclosed |
| WO-2008112164-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-6969582-B2 | Silver halide emulsion containing iridium dopant | EASTMAN KODAK COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050233266-A1 | SILVER HALIDE EMULSION CONTAINING IRIDIUM DOPANT | QUALEX INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105456-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, AK2 | MMP13 3662/4885ALDH1A1 13/4885HTT 2395/4885 |
| US-20110105602-A2 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, AK2 | MMP13 3662/4885ALDH1A1 13/4885HTT 2395/4885 |
| US-20190083457-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS FOR PROTECTING, EXPANDING AND INCREASING THE POTENCY OF HEMATOPOIETIC STEM CELLS | ALDH2, ALDH5A1, ALDH1A1 | MMP13 4174/4885ALDH1A1 3/4885HTT 2565/4885 |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | MMP13 4599/4885ALDH1A1 1194/4885HTT 761/4885 |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | ALDH2, ALDH5A1, AK2 | MMP13 3662/4885ALDH1A1 13/4885HTT 2395/4885 |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, DLD | MMP13 3970/4885ALDH1A1 68/4885HTT 3507/4885 |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | ALDH2, ALDH5A1, DLD | MMP13 3970/4885ALDH1A1 68/4885HTT 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.